Items Tagged ‘Xermelo’

March 1st, 2017

Xermelo-new option for controlling symptoms of Carcinoid Syndrome


The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea. Carcinoid syndrome is a cluster of symptoms that occurs in patients with advanced neuroendocrine tumors (NET) and the related diarrhea results […]

View full entry

Tags: carcinoid syndrome, General, NET, neuroendocrine tumors, News, Other News Topics (not Types of Cancer), Xermelo